{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:35:31Z","timestamp":1767706531044,"version":"3.41.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Menstrual migraine (MM) has a longer duration and higher drug resistance than non-perimenstrual migraine. Calcitonin gene-related peptide (CGRP) and CGRP receptors are expressed in the peripheral and central nervous systems throughout the trigeminovascular system. The CGRP\/CGRP receptor axis plays an important role in sensory physiology and pharmacology. CGRP receptor antagonists and anti-CGRP monoclonal antibodies (mAbs) have shown consistent efficacy and tolerability in the prevention of chronic or episodic migraine and are now approved for clinical use. However, few studies have reported the use of these drugs in MM, and no specific treatment for MM has been approved. This review aimed to shed light on the recent advances in targeting calcitonin gene-related peptides for the treatment of menstrual migraines in PubMed. In this review, we first discuss the axis of the CGRP\/CGRP receptor. We then discuss the role of CGRP receptor antagonists and anti-CGRP mAbs in MM treatment. Finally, we discuss the role of the combination of anti-CGRP mAbs and CGRP receptor antagonists in migraine treatment and the drugs that inhibit CGRP release. Altogether, the anti-CGRP mAbs or CGRP receptor antagonists showed good efficacy and safety in the treatment of MM.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029361","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T13:08:12Z","timestamp":1655471292000},"page":"e29361","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine"],"prefix":"10.1097","volume":"101","author":[{"given":"Yan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-Lun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"R1-20250612","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/14656566.2017.1414182","article-title":"Menstrual migraine: a review of current and developing pharmacotherapies for women","volume":"19","author":"Allais","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"R2-20250612","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/0333102410378049","article-title":"Perimenstrual migraines and their response to preventive therapy with topiramate","volume":"31","author":"Allais","year":"2011","journal-title":"Cephalalgia"},{"key":"R3-20250612","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s10194-018-0896-5","article-title":"Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH)","volume":"19","author":"Sacco","year":"2018","journal-title":"J Headache Pain"},{"key":"R4-20250612","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s10194-017-0815-1","article-title":"Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH)","volume":"18","author":"Sacco","year":"2017","journal-title":"J Headache Pain"},{"key":"R5-20250612","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14737175.2020.1730816","article-title":"low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and suggestions for future research","volume":"20","author":"Ornello","year":"2020","journal-title":"Expert Rev Neurother"},{"key":"R6-20250612","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1097\/AOG.0000000000003072","article-title":"ACOG Practice Bulletin No. 206: use of hormonal contraception in women with coexisting medical conditions","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R7-20250612","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s10194-018-0899-2","article-title":"Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting the Burden: the Global Campaign against Headache","volume":"20","author":"Steiner","year":"2019","journal-title":"J Headache Pain"},{"key":"R8-20250612","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s10072-018-3547-3","article-title":"The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis","volume":"39","author":"Zhu","year":"2018","journal-title":"Neurol Sci"},{"key":"R9-20250612","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12883-020-01633-3","article-title":"Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine: an updated systematic review and meta-analysis","volume":"20","author":"Deng","year":"2020","journal-title":"BMC Neurol"},{"key":"R10-20250612","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/head.13510","article-title":"Calcitonin gene-related peptide modulators\u2014the history and renaissance of a new migraine drug class","volume":"59","author":"Hargreaves","year":"2019","journal-title":"Headache"},{"key":"R11-20250612","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/298240a0","article-title":"Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products","volume":"298","author":"Amara","year":"1982","journal-title":"Nature"},{"key":"R12-20250612","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0014-5793(86)81338-2","article-title":"The calcitonin-like sequence of the beta CGRP gene","volume":"206","author":"Alevizaki","year":"1986","journal-title":"FEBS Lett"},{"key":"R13-20250612","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0306-4522(88)90018-8","article-title":"Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat","volume":"25","author":"Mulderry","year":"1988","journal-title":"Neuroscience"},{"key":"R14-20250612","doi-asserted-by":"crossref","first-page":"16020","DOI":"10.1038\/celldisc.2016.20","article-title":"Erratum: An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology","volume":"2","author":"Gingell","year":"2016","journal-title":"Cell Discov"},{"key":"R15-20250612","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1146\/annurev-pharmtox-010715-103120","article-title":"Receptor activity-modifying proteins (RAMPs): new insights and roles","volume":"56","author":"Hay","year":"2016","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R16-20250612","doi-asserted-by":"crossref","first-page":"03","DOI":"10.1111\/bph.14075","article-title":"Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR review 25","volume":"175","author":"Hay","year":"2018","journal-title":"Br J Pharmacol"},{"key":"R17-20250612","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies: successful translation from bench to clinic","volume":"14","author":"Edvinsson","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"R18-20250612","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","article-title":"CGRP may play a causative role in migraine","volume":"22","author":"Lassen","year":"2002","journal-title":"Cephalalgia"},{"key":"R19-20250612","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/j.pain.0000000000000831","article-title":"The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine","volume":"158","author":"Iyengar","year":"2017","journal-title":"Pain"},{"key":"R20-20250612","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.str.2010.05.014","article-title":"Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism","volume":"18","author":"ter Haar","year":"2010","journal-title":"Structure (Lond)"},{"key":"R21-20250612","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/head.13064","article-title":"CGRP and its receptors","volume":"57","author":"Hay","year":"2017","journal-title":"Headache"},{"key":"R22-20250612","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/0333102417691762","article-title":"CGRP receptor antagonist activity of olcegepant depends on the signalling pathway measured","volume":"38","author":"Walker","year":"2018","journal-title":"Cephalalgia"},{"key":"R23-20250612","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa030505","article-title":"Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine","volume":"350","author":"Olesen","year":"2004","journal-title":"N Engl J Med"},{"key":"R24-20250612","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1212\/WNL.0b013e3181b87942","article-title":"Randomized, controlled trial of telcagepant for the acute treatment of migraine","volume":"73","author":"Connor","year":"2009","journal-title":"Neurology"},{"key":"R25-20250612","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1177\/0333102411398399","article-title":"Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine","volume":"31","author":"Hewitt","year":"2011","journal-title":"Cephalalgia"},{"key":"R26-20250612","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/0333102413500727","article-title":"BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial","volume":"34","author":"Marcus","year":"2014","journal-title":"Cephalalgia"},{"key":"R28-20250612","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1177\/0333102416653233","article-title":"A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine","volume":"36","author":"Voss","year":"2016","journal-title":"Cephalalgia"},{"key":"R29-20250612","doi-asserted-by":"crossref","first-page":"7838","DOI":"10.1021\/jm500364u","article-title":"Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine","volume":"57","author":"Bell","year":"2014","journal-title":"J Med Chem"},{"key":"R30-20250612","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/0333102415584308","article-title":"Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine","volume":"36","author":"Ho","year":"2016","journal-title":"Cephalalgia"},{"key":"R31-20250612","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1526-4610.2010.01799.x","article-title":"Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial","volume":"51","author":"Connor","year":"2011","journal-title":"Headache"},{"key":"R32-20250612","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/WNL.0000000000000771","article-title":"Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention","volume":"83","author":"Ho","year":"2014","journal-title":"Neurology"},{"key":"R33-20250612","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1212\/WNL.0000000000004391","article-title":"Erenumab (AMG 334) in episodic migraine: interim analysis of an ongoing open-label study","volume":"89","author":"Ashina","year":"2017","journal-title":"Neurology"},{"key":"R34-20250612","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1177\/0333102418788347","article-title":"Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study","volume":"38","author":"Ashina","year":"2018","journal-title":"Cephalalgia"},{"key":"R35-20250612","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol"},{"key":"R36-20250612","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.clpt.2004.10.001","article-title":"BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation","volume":"77","author":"Petersen","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R37-20250612","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3390\/brainsci11030370","article-title":"Menstrual headache in women with chronic migraine treated with erenumab: an observational case series","volume":"11","author":"Ornello","year":"2021","journal-title":"Brain Sci"},{"key":"R38-20250612","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s10194-020-01167-6","article-title":"Efficacy and safety of erenumab in women with a history of menstrual migraine","volume":"21","author":"Pavlovic","year":"2020","journal-title":"J Headache Pain"},{"key":"R39-20250612","doi-asserted-by":"crossref","first-page":"e2121","DOI":"10.1212\/WNL.0000000000008944","article-title":"Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy","volume":"94","author":"Mullin","year":"2020","journal-title":"Neurology"},{"key":"R40-20250612","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/head.13930","article-title":"Safety of rimegepant, an oral CGRP receptor antagonist, Plus CGRP monoclonal antibodies for migraine","volume":"60","author":"Berman","year":"2020","journal-title":"Headache"},{"key":"R41-20250612","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/0028-3908(91)90165-8","article-title":"Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion","volume":"30","author":"Buzzi","year":"1991","journal-title":"Neuropharmacology"},{"key":"R42-20250612","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410330109","article-title":"The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats","volume":"33","author":"Goadsby","year":"1993","journal-title":"Ann Neurol"},{"key":"R43-20250612","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1054\/npep.1999.0009","article-title":"Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288","volume":"33","author":"Knight","year":"1999","journal-title":"Neuropeptides"},{"key":"R44-20250612","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/jemt.1081","article-title":"Neurogenic inflammation in the context of migraine","volume":"53","author":"Williamson","year":"2001","journal-title":"Microsc Res Tech"},{"key":"R45-20250612","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1468-2982.1997.1704525.x","article-title":"Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat\u2013intravital microscope studies","volume":"17","author":"Williamson","year":"1997","journal-title":"Cephalalgia"},{"key":"R46-20250612","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1046\/j.1468-2982.1997.1708833.x","article-title":"Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs","volume":"179","author":"Longmore","year":"1997","journal-title":"Cephalalgia"},{"key":"R47-20250612","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0014-2999(97)83028-2","article-title":"The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation","volume":"328","author":"Williamson","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"R48-20250612","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrneurol.2010.127","article-title":"CGRP and its receptors provide new insights into migraine pathophysiology","volume":"6","author":"Ho","year":"2010","journal-title":"Nat Rev Neurol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:00:33Z","timestamp":1749754833000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029361"}},"subtitle":["A narrative review"],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":47,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029361","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"2021-09-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}